Skip to main content

Table 4 ADR reporting rates in 2017a, b

From: Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis

Country Numberof reportsreceivedat the PVcentre Millioninhabitants Reportsper millioninhabitants Number ofTB reportsreceived bythe NTP Numberofpatientswith TB Reports per1000 TBpatients Number ofreports frompatientsincluded inaDSM Numberofpatientson NDR aDSM reportsper 1000patientson NDR
Eswatini 224c 1.2 187 NA (9 MDR-TB) 1374(318 MDR-TB) NA (28.3 MDR-TB) 19d 276d 69
Ethiopia 706 105 6.7 67 117,705 0.6 28e 218e 128
Nigeria 2173 186 11.7 1210 (156)f 109,637 11.0 (1.4)f 5 33 152
Tanzania 287 60 4.8 49 69,818 0.7 114g 129g 884
  1. a Unless otherwise indicated
  2. bAbbreviations used in this table: ADR adverse drug reaction, aDSM active drug safety monitoring and management, NDR new drugs and regimens (i.e. bedaquiline, delamanid, and a shorter treatment regimen), PV pharmacovigilance, TB tuberculosis
  3. cJune 2016 – May 2017
  4. dJanuary 2016 – December 2018
  5. eJuly 2016 – June 2018
  6. fOf the 1210 reports received by the NTP, only 156 were forwarded to NAFDAC. The number of reports per 1000 TB patients was calculated both for all reports received by the NTP, and for the reports that reached the NMRA (in brackets)
  7. gNovember 2017 – July 2018